[Visceral leishmaniasis related to infliximab administration].
Romaní-Costa
Verónica
V
Sánchez
Carlos
C
Moyá
Francesca
F
Estany
Cristina
C
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy*; D048909:Diabetes Complications; D004283:Dog Diseases / Q000469:parasitology; D004285:Dogs; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D007898:Leishmaniasis, Visceral / Q000209:etiology* / Q000635:transmission / Q000662:veterinary; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000209:etiology* / Q000469:parasitology / Q000635:transmission
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D000069285:Infliximab